Abstract BACKGROUND AND PURPOSE Although preclinical results suggest that the
inhibition of erb‐B1 or erb‐B2 can be an useful tool to castration resistant prostate cancer …

Background: The androgen receptor (AR) remains a major therapeutic target in patients with
castration-resistant prostate cancer (CRPC). Enzalutamide, an AR inhibitor that is FDA …

Background: We previously showed that the mTOR pathway is activated in castrate resistant
prostate cancer (CRPC) while inhibition of this pathway upregulated androgen receptor (AR) …

Purpose: ErbB2 signaling appears to be increased and may enhance androgen receptor
(AR) activity in a subset of patients with castration-resistant prostate cancer (CRPC), but …

e15131 Background: Multiple signaling pathways are involved in the development of CRPC.
We previously showed that the mTOR pathway is activated in CRPC cell lines while …

Background Despite overexpression of the ErbB (EGFR/HER2/ErbB3/ErbB4) family in
castration-resistant prostate cancer (CRPC), some inhibitors of this family, including the dual …

Background Prostate tissue expresses 2 estrogen receptor (ER) isoforms, ER-α and ER-β,
and estrogen-based therapies have shown activity in preclinical studies. Raloxifene, a …

BACKGROUND The mammalian target of rapamycin (mTOR) pathway is up‐regulated in
castration‐resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …

A recent phase III trial of the MET kinase inhibitor cabozantinib in men with castration-
resistant prostate cancer (CRPC) failed to meet its primary survival end point; however, most …

Background: Despite the progress and innovation in chemo-and immunotherapies,
androgen deprivation therapy remains the standard treatment of metastatic prostate cancer …